Sort
10,766 grants matching “checkpoint inhibitor”
Cancer Therapy Clinical Trials Using Novel Recombinant Vaccines
$429,318James L. Gulley · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Regulation of immune responses by inhibitory receptors
$429,215Eric O Long · National Institute Of Allergy And Infectious Diseases · ZIA · FY2019 · AI
Role of Erbb3 kinase activity in colorectal tumorigenesis.
$429,115Zhenghe Wang · Case Western Reserve University · R01 · FY2024 · CA
Targeting miRNA-loaded exosomes to HNSCC with Dsg2-directed scFv fusion proteins
$429,000My Georgia Mahoney · Thomas Jefferson University · R21 · FY2024 · DE
Preventing follicular lymphoma progression and transformation through precision therapy
$428,795Wendy Beguelin · Weill Medical Coll Of Cornell Univ · R01 · FY2025 · CA
CARM1-mediated regulation of YAP1 as a therapeutic target in lung cancer
$428,694Joseph Kissil · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2023 · CA
CARM1-mediated regulation of YAP1 as a therapeutic target in lung cancer
$428,692Joseph Kissil · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2022 · CA
Cell-Selective CpG-STAT3 Inhibitors for Radioimmunotherapy of Malignant Glioma
$428,676Marcin Kortylewski · Beckman Research Institute/City Of Hope · R01 · FY2019 · CA
Targeting Transcriptional Regulators for Immunotherapy of Acute Myeloid Leukemia
$428,441Marcin Kortylewski · Beckman Research Institute/City Of Hope · R01 · FY2017 · CA
SynerGel: A Novel Tumor Microenvironment-Modulating Hydrogel for Local Immunotherapy
$428,440Simon Young · University Of Texas Hlth Sci Ctr Houston · R01 · FY2021 · DE
Targeting STAT3 for the Treatment of CDK4/6 Inhibitor Resistant Advanced Estrogen Receptor Positive Breast Cancer Patients
$428,160Khandan Keyomarsi · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA
Targeting NQO1+ tumor to trigger innate and adaptive immunity
$427,984Xiumei Huang · Indiana University Indianapolis · R01 · FY2024 · CA
Role of type 2 immune response in pancreatic cancer tumorigenesis
$427,908Prasenjit Dey · Roswell Park Cancer Institute Corp · R01 · FY2021 · CA
Analysis and Therapeutic Targeting of the Linear-Ubiquitination Pathway in Hodgkin Lymphoma
$427,763Yibin Yang · Research Inst Of Fox Chase Can Ctr · R01 · FY2025 · CA
Analysis and Therapeutic Targeting of the Linear-Ubiquitination Pathway in Hodgkin Lymphoma
$427,763Yibin Yang · Research Inst Of Fox Chase Can Ctr · R01 · FY2021 · CA
Analysis and Therapeutic Targeting of the Linear-Ubiquitination Pathway in Hodgkin Lymphoma
$427,763Yibin Yang · Research Inst Of Fox Chase Can Ctr · R01 · FY2022 · CA
ALDH Inhibition as Modulator of Tumor Immunobiology
$427,724Ronald J Buckanovich · Magee-Women'S Res Inst And Foundation · R01 · FY2023 · CA
PROTAC Targeting of Tip60 in Syngeneic Cancer Models Using Cereblon Knock-in Mice
$427,654Wayne William Hancock · Children'S Hosp Of Philadelphia · R01 · FY2020 · CA
Novel Roles of TAZ and YAP in DNA Damage Repair with 3D Genome Organization and the Therapeutic Resistance in Glioblastoma
$427,263Krishna Pl Bhat · Mayo Clinic Arizona · R01 · FY2024 · NS
Signaling Pathways in Neuronal Cells
$427,217Marsha R Rosner · University Of Chicago · R01 · FY2010 · GM
Targeting Posttranslational Modifications in Breast Carcinogenesis
$427,217Yong Wan · Emory University · R01 · FY2024 · CA
Exploiting immunostimulatory microbial pattern recognition to improve head and neck cancer therapy
$427,208Xiang-Yang Wang · Virginia Commonwealth University · R01 · FY2025 · DE
Targeting PLK1 in RAS mutant chronic myelomonocytic leukemia
$427,131Mrinal Shiv Patnaik · Mayo Clinic Rochester · R01 · FY2023 · CA
Targeting PLK1 in RAS mutant chronic myelomonocytic leukemia
$427,131Mrinal Shiv Patnaik · Mayo Clinic Rochester · R01 · FY2025 · CA
Targeting exosomal PDL1 to improve immunotherapy
$426,960Wei Guo · Wistar Institute · P50 · FY2024 · CA